| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101637 | PLX PHARMA | Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Mar, 2022
(1 year, 6 months ago) | |
| US8865187 | PLX PHARMA | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Mar, 2022
(1 year, 6 months ago) | |
| US10786444 | PLX PHARMA | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(9 years from now) | |
| US10646431 | PLX PHARMA | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(9 years from now) | |
| US9226892 | PLX PHARMA | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(9 years from now) | |
| US9216150 | PLX PHARMA | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(9 years from now) | |
Vazalore is owned by Plx Pharma.
Vazalore contains Aspirin.
Vazalore has a total of 6 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vazalore are:
- US9101637
- US8865187
Vazalore was authorised for market use on 14 January, 2013.
Vazalore is available in capsule;oral dosage forms.
Vazalore can be used as treatment/prevention of cardiovascular disease; temporary reduction of fever; temporary relief of minor aches and pains, treatment/prevention of cardiovascular disease; temporary relief of minor aches and pains; temporary reduction of fever, a method of targeting release of a non-steroidal anti-inflammatory drug (nsaid) to the small intestine of the subject when administered orally.
The generics of Vazalore are possible to be released after 29 September, 2032.
Drugs and Companies using ASPIRIN ingredient
Market Authorisation Date: 14 January, 2013
Treatment: Treatment/prevention of cardiovascular disease; Temporary reduction of fever; Temporary relief of minor aches and pains; A method of targeting release of a non-steroidal anti-inflammatory drug (nsaid)...
Dosage: CAPSULE;ORAL
VAZALORE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic